Invo Fertility, Inc. · NASDAQ:IVF
Invo Fertility — Investor Presentation (June 2026)
27 slides from Invo Fertility's investor presentation, Jun 16, 2026
Slide 1: Life Begins Within
| LIFE BEGINS WITHIN OmBier JUNE 2026 CORPORATE PRESENTATION
Slide 2: Forward-looking statements
Ovo teriility NASDAQ: We ‘This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements made in this presentation that are not of a historical natur
Slide 3: Our Mission
a a OUR MISSION O)INVO fertility We are a healthcare fertility company focused on making advanced fertility care effective, accessible, and empowering for all, through a patient- centered approach that is powered by innovation, compassion and an exceptional team.
Slide 4: Company Evolution: Expanding Our Focus in the Fertility Market
Oinvoreriility NASDAQ: IVF COMPANY EVOLUTION EXPANDING OUR FOCUS IN THE FERTILITY MARKET Beyond our device heritage to a comprehensive healthcare provider Proprietary and novel innovative medical device that 4 Operating clinics (Wisconsin, Indiana, Georgia, allows fertilization and embryo incubation
Slide 5: Why Now: An Inflection Point
Oinvoterlity NASDAQ: IVF WHY NOW AN INFLECTION POINT STRUCTURAL OPERATIONAL Improved capital structure + All Series C-2 preferred converted or retired and warrant liabilities eliminated; the structure is now cleaner and simplified + Recentraise was done ata fixed price - @ $7.95 + ~1.8 million share
Slide 6: Fertility Centers
Slide 7: Fertility Market: Scale, Growth and Consolidation
Ovo: NASDAQ: IVF FERTILITY Market U.S. IVE MARKET: U.S. ART Clinics by Ownership Type ? SCALE, GROWTH + CONSOLIDATION TAILWINDS + Market size & growth (U.S. IVF) *(2023) + ~$5.7B + Est 5.1% CAGR (2024-2030) * Clinic landscape (U.S.) 22022) + 457 reporting ART clinics + 435,426 ART cycles performed =
Slide 8: Mission and Growth Strategy
Oinvoreriility NASDAQ: IVF MISSION AND GROWTH STRATEGY BECOME A LEADING PROVIDER OF FERTILITY SERVICES AND TECHNOLOGY Acquisitions bring accelerated bulk to operat term sustainable operations ns and faster pathway to overall pro bility. Setting the company up for long- Robust pipeline. Active discus
Slide 9: Fertility Centers
NASDAQ: IVF FERTILITY CENTERS 1000+ CYCLES IN 2025 ACROSS 4 FERTILITY CENTERS wi nsin ae MSS SO Sit bloom fertility INNOVATIVE @) LOCATION Middleton, WI Atlanta, GA Birmingham, AL Indianapolis, IN? PROCEDURES IVF,IVC planned NC, IVF planned IVF and IVC IVF and IVC ANNUAL CYCLES ~500 ~150 ~150 ~200 P
Slide 10: Case Study - M&A Strategy: Wisconsin Fertility Institute
ea a CASE STUDY - M&A STRATEGY WISCONSIN FERTILITY INSTITUTE Acquisition Details * One of Wisconsin's leading fertility centers (rated top-100 in US by Newsweek) + 5,000+ babies born since 2007, averaged 500+ IVF cycles/year over the last 5 years + Strong team in place with room for growth wisc®nsin
Slide 11: Why Clinics Join INVO Fertility
OINvo Fertility NASDAQ: IVF ADVANTAGES WHY CLINICS JOIN INVO FERTILITY Like-Minded Partners; Synergies Focus on medical practice and patient services, while INVO corporate provides centralized administration, finance, marketing, human resources and other services Strength in unity - generate synergi
Slide 12: Technology
Slide 13: Leveraging Technology to Expand Access
Oinvoterility LEVERAGING TECHNOLOGY TO EXPAND ACCESS Medical device heritage Unique INVOcell-enabled IVC procedure improves lab efficiency and capacity, increases fertility service supply and helps to reduce the risk of mix- up occurrences, while providing a more connected patience experience. A new
Slide 14: INVOcell: Unique Product, Revolutionary Procedure
INVOcell® UNIQUE PRODUCT, REVOLUTIONARY PROCEDURE For clinical pregnancy rates, INVOcell outcomes are comparable to IVF and more effective than IUI. [——__ 20VANCED TREATMENT =a lUul 8-10%* INVOcell (IVC) =57..on" IVF ~5 1S zane SUCCESS SUCCESS SUCCESS
Slide 15: mo. vy +
mo. vy +
Slide 16: Revenue & Adjusted EBITDA
OINvo Fertility NASDAQ: IVF REVENUE & ADJUSTED EBITDA CONSOLIDATED REVENUE ($ M se $0 $6.8 & os ws i & (32) — (33) = $s ($9.2) (s4) a (ss) 9 0 ($5.1) (s6) & (s7) 1 a (se) . — = a0 2022 2023 2028 2025, 2022 2023 2024 2025 ns) ADJUSTED EBITDA($ Millions) 1 Adjusted EBITDA details are provided in Appen
Slide 17: Balance Sheet Highlights
NASDAQ: IVF BALANCE SHEET HIGHLIGHTS 550) zen028 J zsnrzoze | 31025 | EES Cash and eash equivalents 232.424 619520 Worrant inducement Pied Atte: Malet Under Nesdea Rules Other eurent assets 1027351 437,038 683.664 Lease right of use 5,740,929 1,493,620 1,286,217 Intangible assets 4,093,431 3,275,931
Slide 18: Cap Structure
Oyinvoeeriiir NASDAQ: IVF CAP STRUCTURE CS Market capitalization $2.6M Stock price $1.48 Common shares issued and outstanding 1.786 M Warrants outstanding 2.05 M at Avg. of $12.99 (~1.9 mil @ $7.95) Options, etc outstanding 0.009 M at Avg. $578.86 Conversion of debt and preferred (if converted) 0.6M
Slide 19: Summary
Onvo NASDAQ LIVE SUMMARY
Slide 20: Why Invest in INVO Fertility? Key Takeaways
OINVO fertility NASDAQ: IVF WHY INVEST IN INVO FERTILITY? KEY TAKEAWAYS L Growing Clinic Operations + 4-current fully operational fertility clinics Organic growth initiatives underway grew from $0.8M in + Consolidated revenue M&A Focus to Drive Added Growth + Prioritizing M&A over newly built clinic
Slide 21: People
Slide 22: Leadership Team
O INV teriilty NASDAQ: IVF LEADERSHIP TEAM EXPERIENCED & DEDICATED @ Gretchen Collins Sue Ellen Carpenter___Nick Cataldo James Donahue! ; ay, a wise@nsin INNOVATIVE @) bloom fertility — INN@NATINE Steve Shum CEO Doctors Andrea Goren Terah Krigsvold fertility MaA/Legal Finance/Accounting £ 9 .] £ fa)
Slide 23: Board of Directors
Oinvoreriility NASDAQ: IVF BOARD OF DIRECTORS INDEPENDENT & ENGAGED Steve Shum Trent Davis Rebecca Messina Barbara Ryan Matthew Szot CEO, Director Independent Director Independent Director Independent Director Independent Director “CRAP Srns ecnary Catnng a BEAR CADRENAL EASTSIDE Cetble STEARNS ADRE
Slide 24: Thank You
Slide 25: Appendix
mo. vy + rs APPENDIX —
Slide 26: Income Statement Highlights
Oinvoteriiity NASDAQ: IVF INCOME STATEMENT HIGHLIGHTS A CS Clinic 614,954 2,862,574 6,450,431 6,721,087 Product 207,342 158,001 81,569 120,193 Revenue 822,196 3.020575 6,832,000 6,841,250 Opex 11,448,677 9,787,730 13,159,713 14,078,606 Op loss (10,626,481) (6,767,155) (6,627,718) (7,237,356) Other i
Slide 27: Adjusted EBITDA
Oinvoteriiity NASDAQ: IVF ADJUSTED EBITDA LS Net loss from continuing operations (10,892,511) (8,034,612) (7,739,953) (5,335,975) Interest expense 7.109 205,781 412,860 119.095, Amortization of debt discount 52,644 720,128 622,283 1,182,979 Foreign curreney exchange loss 3,463 429 = = ‘Tax expense (